PDS Biotech prioritizes triple combo for HPV+ HNSCC; 75% 36-mo survival in Ph2

PDS Biotechnology Corp

Three-year OS of 75% and 75% ORR in ICI-naive advanced HNSCC with PDS01ADC + Versamune HPV + KEYTRUDA.
ICI-resistant group: 72% 12-month OS and 63% ORR at optimal PDS01ADC dose; median OS ~20 months.
Full-year 2023 net loss $42.9M ($1.39/sh) vs $40.9M ($1.43/sh) in 2022; cash $56.6M at Dec 31.
Company raised ~$10.5M net via ATM in Q4 2023 and appointed new CMO and CFO in late 2023/early 2024.
VERSATILE-003 trial deprioritized; potentially pivotal randomized trial of triple combo expected to start in 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PDS Biotechnology Corp reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share, EPS $1.39 per basic and diluted share.

Period: the year ended December 31, 2023
Net income: Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share
EPS: $1.39 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share, compared to a net loss of $40.9 million, or $1.43 per basic share and diluted share, for the year ended December 31, 2022.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-24-015456

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.